{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:55:26Z","timestamp":1790391326808,"version":"4.1.0"},"reference-count":98,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Medical Research"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.arcmed.2020.06.018","type":"journal-article","created":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T01:07:37Z","timestamp":1594343257000},"page":"765-776","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["An Update on Gastroenteropancreatic Neuroendocrine Neoplasms: From Mysteries to Paradigm Shifts"],"prefix":"10.1016","volume":"51","author":[{"given":"Claudia","family":"Ram\u00edrez-Renter\u00eda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo","family":"Ferreira-Hermosillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Marrero-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Taniguchi-Ponciano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virgilio","family":"Melgar-Manzanilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mois\u00e9s","family":"Mercado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arcmed.2020.06.018_bib1","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1038\/onc.2016.316","article-title":"Translational research in neuroendocrine tumors: pitfalls and opportunities","volume":"36","author":"Capdevila","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.arcmed.2020.06.018_bib2","doi-asserted-by":"crossref","first-page":"78","DOI":"10.6004\/jnccn.2015.0011","article-title":"Neuroendocrine tumors, version 1.2015","volume":"13","author":"Kulke","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.arcmed.2020.06.018_bib3","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1155\/2008\/270905","article-title":"Requiem for the term 'carcinoid tumour' in the gastrointestinal tract?","volume":"22","author":"Chetty","year":"2008","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.arcmed.2020.06.018_bib4","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1038\/s41379-018-0110-y","article-title":"A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal","volume":"31","author":"Rindi","year":"2018","journal-title":"Mod Pathol"},{"issue":"suppl 1","key":"10.1016\/j.arcmed.2020.06.018_bib5","doi-asserted-by":"crossref","first-page":"e490s","DOI":"10.6061\/clinics\/2018\/e490s","article-title":"Carcinoid syndrome: update on the pathophysiology and treatment","volume":"73","author":"Rubin de Celis Ferrari","year":"2018","journal-title":"Clinics (Sao Paulo)"},{"key":"10.1016\/j.arcmed.2020.06.018_bib6","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1677\/joe.1.06964","article-title":"The neuroendocrine system of invertebrates: a developmental and evolutionary perspective","volume":"190","author":"Hartenstein","year":"2006","journal-title":"J Endocrinol"},{"key":"10.1016\/j.arcmed.2020.06.018_bib7","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1159\/000334612","article-title":"Diffuse endocrine system, neuroendocrine tumors and immunity: what's new?","volume":"95","author":"Ameri","year":"2012","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.arcmed.2020.06.018_bib8","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1007\/s00423-011-0794-7","article-title":"The archaic distinction between functioning and nonfunctioning neuroendocrine neoplasms is no longer clinically relevant","volume":"396","author":"Modlin","year":"2011","journal-title":"Langenbecks Arch Surg"},{"key":"10.1016\/j.arcmed.2020.06.018_bib9","doi-asserted-by":"crossref","first-page":"19245","DOI":"10.18632\/oncotarget.24983","article-title":"Global burden of neuroendocrine tumors and changing incidence in Kentucky","volume":"9","author":"Chauhan","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.arcmed.2020.06.018_bib10","doi-asserted-by":"crossref","DOI":"10.1177\/2042018819828217","article-title":"Economics of gastroenteropancreatic neuroendocrine tumors: a systematic review","volume":"10","author":"Grande","year":"2019","journal-title":"Ther Adv Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2020.06.018_bib11","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.arcmed.2020.06.018_bib12","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1200\/JGO.2015.002980","article-title":"Patient-Reported Burden of a Neuroendocrine Tumor (NET) Diagnosis: Results From the First Global Survey of Patients With NETs","volume":"3","author":"Singh","year":"2017","journal-title":"J Glob Oncol"},{"key":"10.1016\/j.arcmed.2020.06.018_bib13","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/cncr.29099","article-title":"Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes","volume":"121","author":"Hallet","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.arcmed.2020.06.018_bib14","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1186\/s12885-019-5543-2","article-title":"Non-functional pancreatic neuroendocrine tumours: emerging trends in incidence and mortality","volume":"19","author":"Wu","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.arcmed.2020.06.018_bib15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12672-018-0354-5","article-title":"Chilean Registry for Neuroendocrine Tumors: A Latin American Perspective","volume":"10","author":"Pinto","year":"2019","journal-title":"Horm Cancer"},{"key":"10.1016\/j.arcmed.2020.06.018_bib16","first-page":"243","article-title":"[Surgical prognostic factors of gastroenteropancreatic neuroendocrine tumors (GEP NET)]","volume":"50","author":"Medrano-Guzman","year":"2012","journal-title":"Rev Med Inst Mex Seguro Soc"},{"key":"10.1016\/j.arcmed.2020.06.018_bib17","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.gamo.2015.07.003","article-title":"Tumores neuroendocrinos: experiencia de 6 a\u00f1os en un centro de tercer nivel","volume":"14","author":"Villa-Grajeda","year":"2015","journal-title":"Gaceta Mexicana de Oncolog\u00eda"},{"issue":"15_suppl","key":"10.1016\/j.arcmed.2020.06.018_bib18","doi-asserted-by":"crossref","first-page":"e15647","DOI":"10.1200\/JCO.2016.34.15_suppl.e15647","article-title":"Observational study of neuroendocrine tumors in a Mexican cohort","volume":"34","author":"Hernandez","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.arcmed.2020.06.018_bib19","doi-asserted-by":"crossref","first-page":"673","DOI":"10.3892\/mco.2014.332","article-title":"Observational study of patients with gastroenteropancreatic and bronchial neuroendocrine tumors in Argentina: Results from the large database of a multidisciplinary group clinical multicenter study","volume":"2","author":"O'Connor","year":"2014","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.arcmed.2020.06.018_bib20","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1590\/S0104-42302008000400014","article-title":"Neuroendocrine tumors: a registry of 1,000 patients","volume":"54","author":"Younes","year":"2008","journal-title":"Rev Assoc Med Bras (1992)"},{"key":"10.1016\/j.arcmed.2020.06.018_bib21","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1530\/ERC-16-0099","article-title":"Ki-67 index and response to chemotherapy in patients with neuroendocrine tumours","volume":"23","author":"Childs","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.arcmed.2020.06.018_bib22","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.hoc.2015.08.006","article-title":"Clinical Presentation and Diagnosis of Neuroendocrine Tumors","volume":"30","author":"Vinik","year":"2016","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.arcmed.2020.06.018_bib23","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1186\/s12885-018-5057-3","article-title":"Delays and routes to diagnosis of neuroendocrine tumours","volume":"18","author":"Basuroy","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.arcmed.2020.06.018_bib24","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1245\/s10434-011-1832-y","article-title":"Surgery versus intra-arterial therapy for neuroendocrine liver metastasis: a multicenter international analysis","volume":"18","author":"Mayo","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.arcmed.2020.06.018_bib25","first-page":"150032","article-title":"Pancreatic neuroendocrine tumors with transformation to insulinoma: an unusual presentation of a rare disease","volume":"2015","author":"Nahmias","year":"2015","journal-title":"Endocrinol Diabetes Metab Case Res"},{"key":"10.1016\/j.arcmed.2020.06.018_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctrv.2018.04.013","article-title":"Diabetes and pancreatic neuroendocrine tumours: Which interplays, if any?","volume":"67","author":"Gallo","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.arcmed.2020.06.018_bib27","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000488510","article-title":"Presenting Symptoms and Delay in Diagnosis of Gastrointestinal and Pancreatic Neuroendocrine Tumours","volume":"107","author":"Basuroy","year":"2018","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.arcmed.2020.06.018_bib28","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s11154-016-9394-8","article-title":"Flushing in (neuro)endocrinology","volume":"17","author":"Hannah-Shmouni","year":"2016","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.arcmed.2020.06.018_bib29","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jacc.2016.12.030","article-title":"Diagnosing and Managing Carcinoid Heart Disease in Patients With Neuroendocrine Tumors: An Expert Statement","volume":"69","author":"Davar","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.arcmed.2020.06.018_bib30","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1016\/j.amjcard.2010.01.017","article-title":"Echocardiographic follow-up of treated patients with carcinoid syndrome","volume":"105","author":"Mansencal","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.arcmed.2020.06.018_bib31","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/bjc.2014.468","article-title":"Serial surveillance of carcinoid heart disease: factors associated with echocardiographic progression and mortality","volume":"111","author":"Dobson","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.arcmed.2020.06.018_bib32","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s11154-017-9430-3","article-title":"When should genetic testing be performed in patients with neuroendocrine tumours?","volume":"18","author":"O'Shea","year":"2017","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.arcmed.2020.06.018_bib33","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1530\/EJE-19-0877","article-title":"Management of endocrine disease: Cushing's syndrome due to ectopic ACTH secretion: an expert operational opinion","volume":"182","author":"Young","year":"2020","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.arcmed.2020.06.018_bib34","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s12020-012-9790-0","article-title":"Ectopic acromegaly due to growth hormone releasing hormone","volume":"43","author":"Ghazi","year":"2013","journal-title":"Endocrine"},{"key":"10.1016\/j.arcmed.2020.06.018_bib35","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1677\/ERC-10-0028","article-title":"MEN1 in pancreatic endocrine tumors: analysis of gene and protein status in 169 sporadic neoplasms reveals alterations in the vast majority of cases","volume":"17","author":"Corbo","year":"2010","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.arcmed.2020.06.018_bib36","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1053\/j.seminoncol.2012.11.005","article-title":"The genetics of neuroendocrine tumors","volume":"40","author":"Oberg","year":"2013","journal-title":"Semin Oncol"},{"key":"10.1016\/j.arcmed.2020.06.018_bib37","first-page":"105","article-title":"Overview of genetically determined diseases\/multile endocrine neoplasia syndromes predisposing to endocrine tumors","volume":"111","author":"Decmann","year":"2019","journal-title":"Exp Suppl"},{"key":"10.1016\/j.arcmed.2020.06.018_bib38","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1126\/science.1200609","article-title":"DAXX\/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors","volume":"331","author":"Jiao","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.arcmed.2020.06.018_bib39","doi-asserted-by":"crossref","first-page":"E374","DOI":"10.1210\/jc.2013-2782","article-title":"MEN1 gene mutation and reduced expression are associated with poor prognosis in pulmonary carcinoids","volume":"99","author":"Swarts","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2020.06.018_bib40","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1210\/jc.2017-02434","article-title":"In silico VHL gene mutation analysis and prognosis of pancretic neuroendocrine tumors in von Hippel-Lindau disease","volume":"103","author":"Tirosh","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2020.06.018_bib41","first-page":"565","article-title":"Loss of PTEN and increased pAKT expression distinguishes aggressive low-grade neuroendocrine tumors","volume":"48","author":"Jayakumar","year":"2018","journal-title":"Ann Clin Lab Sci"},{"key":"10.1016\/j.arcmed.2020.06.018_bib42","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nature21063","article-title":"Whole-genome landscape of pancreatic neuroendocrine tumours","volume":"543","author":"Scarpa","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.arcmed.2020.06.018_bib43","doi-asserted-by":"crossref","first-page":"R161","DOI":"10.1530\/JOE-17-0560","article-title":"Genomic landscape of pancreatic neuroendocrine tumours: the International Cancer Genome Consortium","volume":"236","author":"Mafficini","year":"2018","journal-title":"J Endocrinol"},{"key":"10.1016\/j.arcmed.2020.06.018_bib44","doi-asserted-by":"crossref","first-page":"R315","DOI":"10.1530\/ERC-17-0012","article-title":"Genetic and epigenetic drivers of neuroendocrine tumours (NET)","volume":"24","author":"Di Domenico","year":"2017","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.arcmed.2020.06.018_bib45","doi-asserted-by":"crossref","first-page":"R65","DOI":"10.1530\/ERC-12-0338","article-title":"Neuroendocrine tumours: cracking the epigenetic code","volume":"20","author":"Karpathakis","year":"2013","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.arcmed.2020.06.018_bib46","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1159\/000368363","article-title":"Neuroendocrine tumor biomarkers: current status and perspectives","volume":"100","author":"Modlin","year":"2014","journal-title":"Neuroendocrinology"},{"issue":"Suppl 1","key":"10.1016\/j.arcmed.2020.06.018_bib47","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1530\/ERC-10-0280","article-title":"Circulating biomarkers in gastroenteropancreatic neuroendocrine tumours","volume":"18","author":"Oberg","year":"2011","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.arcmed.2020.06.018_bib48","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1245\/s10434-010-1006-3","article-title":"Chromogranin A\u2013biological function and clinical utility in neuro endocrine tumor disease","volume":"17","author":"Modlin","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.arcmed.2020.06.018_bib49","doi-asserted-by":"crossref","first-page":"e0154679","DOI":"10.1371\/journal.pone.0154679","article-title":"Circulating Chromogranin A as a marker for monitoring clinical response in advanced gastroenteropancreatic neuroendocrine tumors","volume":"11","author":"Tian","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.arcmed.2020.06.018_bib50","doi-asserted-by":"crossref","first-page":"R11","DOI":"10.1530\/ERC-17-0269","article-title":"Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame","volume":"25","author":"Marotta","year":"2018","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.arcmed.2020.06.018_bib51","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/MED.0000000000000215","article-title":"Chromogranin A: any relevance in neuroendocrine tumors?","volume":"23","author":"Kidd","year":"2016","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.arcmed.2020.06.018_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5114\/aoms.2016.57577","article-title":"Chromogranin A - unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls","volume":"12","author":"Gut","year":"2016","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.arcmed.2020.06.018_bib53","doi-asserted-by":"crossref","first-page":"8126087","DOI":"10.1155\/2018\/8126087","article-title":"Chromogranin A: From Laboratory to Clinical Aspects of Patients with Neuroendocrine Tumors","volume":"2018","author":"Di Giacinto","year":"2018","journal-title":"Int J Endocrinol"},{"key":"10.1016\/j.arcmed.2020.06.018_bib54","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1530\/EC-19-0269","article-title":"Measurement of urinary 5-HIAA: correlation between spot versus 24 h urine collection","volume":"8","author":"Calanchini","year":"2019","journal-title":"Endocr Connect"},{"key":"10.1016\/j.arcmed.2020.06.018_bib55","doi-asserted-by":"crossref","first-page":"IJE14","DOI":"10.2217\/ije-2017-0012","article-title":"Applying the use of novel biomarkers for neuroendocrine tumors in the clinic: where are we now?","volume":"6","author":"Daskalakis","year":"2019","journal-title":"Int J Endocrine Oncol"},{"key":"10.1016\/j.arcmed.2020.06.018_bib56","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s00259-015-3250-z","article-title":"Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors","volume":"43","author":"Bodei","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.arcmed.2020.06.018_bib57","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1007\/s00330-015-3770-8","article-title":"Cost-effectiveness modelling in diagnostic imaging: a stepwise approach","volume":"25","author":"Sailer","year":"2015","journal-title":"Eur Radiol"},{"key":"10.1016\/j.arcmed.2020.06.018_bib58","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2174\/1874471012666190214165845","article-title":"Imaging of pancreatic neuroendocrine tumours: An outline of conventional radiological techniques","volume":"12","author":"Zamir","year":"2019","journal-title":"Curr Radiopharm"},{"key":"10.1016\/j.arcmed.2020.06.018_bib59","doi-asserted-by":"crossref","first-page":"405","DOI":"10.5009\/gnl.2012.6.4.405","article-title":"Endoscopic ultrasound in gastroenteropancreatic neuroendocrine tumors","volume":"6","author":"Kim","year":"2012","journal-title":"Gut Liver"},{"key":"10.1016\/j.arcmed.2020.06.018_bib60","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.2967\/jnumed.116.179234","article-title":"Molecular imaging of gastroenteropancreatic neuroendocrine tumors: current status and future directions","volume":"57","author":"Deroose","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1016\/j.arcmed.2020.06.018_bib61","doi-asserted-by":"crossref","first-page":"74","DOI":"10.2174\/1874471010666170323115136","article-title":"Nuclear medicine in patients with NET: Radiolabelled somatostatin analogues and their brothers","volume":"10","author":"Cucurullo","year":"2017","journal-title":"Curr Radiopharm"},{"key":"10.1016\/j.arcmed.2020.06.018_bib62","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.clinimag.2019.04.006","article-title":"Molecular imaging and therapy of somatostatin receptor positive tumors","volume":"56","author":"Ivanidze","year":"2019","journal-title":"Clin Imaging"},{"key":"10.1016\/j.arcmed.2020.06.018_bib63","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/jlcr.3750","article-title":"Exendin-4 analogs in insulinoma theranostics","volume":"62","author":"Jansen","year":"2019","journal-title":"J Labelled Comp Radiopharm"},{"key":"10.1016\/j.arcmed.2020.06.018_bib64","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1007\/s00259-015-3027-4","article-title":"Nuclear imaging of neuroendocrine tumorswith unknown primary: why, when and how?","volume":"42","author":"SanhananP","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.arcmed.2020.06.018_bib65","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2217\/ije.14.40","article-title":"Imaging in neuroendocrine tumors: an update for the clinician","volume":"2","author":"Maxwell","year":"2015","journal-title":"Int J Endocr Oncol"},{"key":"10.1016\/j.arcmed.2020.06.018_bib66","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1159\/000461583","article-title":"ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors","volume":"105","author":"Kaltsas","year":"2017","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.arcmed.2020.06.018_bib67","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.neo.2017.09.002","article-title":"Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas","volume":"19","author":"Oronsky","year":"2017","journal-title":"Neoplasia"},{"key":"10.1016\/j.arcmed.2020.06.018_bib68","doi-asserted-by":"crossref","first-page":"9871319","DOI":"10.1155\/2019\/9871319","article-title":"Primary Tumor Site Affects Survival in Patients with Gastroenteropancreatic and Neuroendocrine Liver Metastases","volume":"2019","author":"Tierney","year":"2019","journal-title":"International journal of endocrinology"},{"key":"10.1016\/j.arcmed.2020.06.018_bib69","doi-asserted-by":"crossref","first-page":"973946","DOI":"10.1155\/2012\/973946","article-title":"Treatment of neuroendocrine tumor liver metastases","volume":"2012","author":"Lewis","year":"2012","journal-title":"Int J Hepatol"},{"key":"10.1016\/j.arcmed.2020.06.018_bib70","doi-asserted-by":"crossref","first-page":"452343","DOI":"10.4061\/2011\/452343","article-title":"Multimodal, liver-directed management of neuroendocrine hepatic metastasis","volume":"2011","author":"Lewis","year":"2011","journal-title":"Int J Hepatol"},{"key":"10.1016\/j.arcmed.2020.06.018_bib71","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nrclinonc.2016.195","article-title":"RECIST- Learninig from the past to build the future","volume":"14","author":"Litiere","year":"2017","journal-title":"Nat Rev Oncol"},{"key":"10.1016\/j.arcmed.2020.06.018_bib72","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/cen.13528","article-title":"Multidisciplinary management of refractory insulinomas","volume":"88","author":"Brown","year":"2018","journal-title":"Clin Endocrinol"},{"issue":"suppl 1","key":"10.1016\/j.arcmed.2020.06.018_bib73","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1530\/eje.1.02354","article-title":"Novel insights insomatostatian receptor physiology","volume":"15","author":"Tulipano","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.arcmed.2020.06.018_bib74","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3389\/fendo.2014.00007","article-title":"Somatostatin analogs therapy in gastroenteropancreatic neuroendocrine tumors: current aspects and new perspectives","volume":"5","author":"Baldelli","year":"2014","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.arcmed.2020.06.018_bib75","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.hoc.2015.09.008","article-title":"Role of Somatostatin Analogues in the Treatment of Neuroendocrine Tumors","volume":"30","author":"Narayanan","year":"2016","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.arcmed.2020.06.018_bib76","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.arcmed.2020.06.018_bib77","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000443612","article-title":"Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival","volume":"104","author":"Rinke","year":"2017","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.arcmed.2020.06.018_bib78","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arcmed.2020.06.018_bib79","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.beem.2015.10.005","article-title":"Peptide receptor radionuclide therapy of neuroendocrine tumours","volume":"30","author":"Brabander","year":"2016","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2020.06.018_bib80","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000446115","article-title":"Systematic Review of the Role of Targeted Therapy in Metastatic Neuroendocrine Tumors","volume":"104","author":"Lee","year":"2017","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.arcmed.2020.06.018_bib81","first-page":"6601","article-title":"Role of interferon-alpha in patients with neuroendocrine tumors: a retrospective study","volume":"34","author":"Mirvis","year":"2014","journal-title":"Anticancer Res"},{"key":"10.1016\/j.arcmed.2020.06.018_bib82","first-page":"29","article-title":"From Chemotherapy to Targeted Therapies: Current Treatment of Carcinoid Tumors and Pancreatic Neuroendocrine Tumors","volume":"1","author":"Stricker","year":"2011","journal-title":"J Hematol Oncol Pharm"},{"key":"10.1016\/j.arcmed.2020.06.018_bib83","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1177\/1756283X16674660","article-title":"Everolimus in the management of metastatic neuroendocrine tumours","volume":"10","author":"Chan","year":"2017","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.arcmed.2020.06.018_bib84","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1200\/JCO.2009.24.2669","article-title":"Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial","volume":"28","author":"Yao","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.arcmed.2020.06.018_bib85","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(11)61742-X","article-title":"Everolimus plus octreotide long acting repeatable for the treatment of advanced neuroendocrine tumors associated wth carcinoid syndrome (RADIANT-2): a randomized, placebo-controlled, phase 3 study","volume":"378","author":"Pavel","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.arcmed.2020.06.018_bib86","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"RAD001 in advanced neuroendocrine tumors, third trial (RADIANT-3) Study Group. Everolimus for\u00a0advanced neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl Med"},{"key":"10.1016\/j.arcmed.2020.06.018_bib87","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"RAD001 in advanced non-functioaal neuroendocrine tumors of the lung or gastrointestinal tract (RADIANT-4): a randomized, placebo-controlled, phase 3 study","volume":"387","author":"Yao","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.arcmed.2020.06.018_bib88","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N Engl Med"},{"key":"10.1016\/j.arcmed.2020.06.018_bib89","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1159\/000491999","article-title":"Efficacy and safety of sunitinib in patients with well-differentiated neuroendocrine tumors","volume":"107","author":"Raymond","year":"2018","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.arcmed.2020.06.018_bib90","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00280-018-3724-3","article-title":"Real-world use of sunitinib in patients with well-differentiated pancreatic neuroendocrine tumors","volume":"83","author":"Sato","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.arcmed.2020.06.018_bib91","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1001\/jamaoncol.2018.6720","article-title":"Therapeutic options for neuroendocrine tumors: A systematic review and network meta-analysis","volume":"5","author":"Kaderli","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.arcmed.2020.06.018_bib92","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1634\/theoncologist.2015-0470","article-title":"The role of capecitibine\/temozolomide in metastatic neuroendocrine tumors","volume":"21","author":"Ram\u00edrez","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.arcmed.2020.06.018_bib93","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/annonc\/mds276","article-title":"Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study","volume":"24","author":"Sorbye","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.arcmed.2020.06.018_bib94","doi-asserted-by":"crossref","first-page":"R375","DOI":"10.1530\/ERC-17-0507","article-title":"Open issues on G3 neuroendocrine neoplasms: back to the future","volume":"25","author":"Zatelli","year":"2018","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.arcmed.2020.06.018_bib95","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1007\/s12020-019-01838-8","article-title":"The prognosis and management of neuroendocrine neoplasms-related bone disease: lessons from clinical practice","volume":"64","author":"AlexandrakiK","year":"2019","journal-title":"Endocrine"},{"key":"10.1016\/j.arcmed.2020.06.018_bib96","article-title":"Identification of areas for improvement in the management of bone metastasis in patients with neuroendocrine neoplasms","author":"Lim","year":"2019","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.arcmed.2020.06.018_bib97","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1097\/MPA.0b013e318249d8f7","article-title":"Clinical burden of illness in patients with neuroendocrine tumors","volume":"41","author":"Hess","year":"2012","journal-title":"Pancreas"},{"key":"10.1016\/j.arcmed.2020.06.018_bib98","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s11154-018-9466-z","article-title":"Nutrition and neuroendocrine tumors: An update of the literature","volume":"19","author":"Altieri","year":"2018","journal-title":"Rev Endocr Metab Disord"}],"container-title":["Archives of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S018844092030535X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S018844092030535X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T19:48:57Z","timestamp":1759261737000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S018844092030535X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":98,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S018844092030535X"],"URL":"https:\/\/doi.org\/10.1016\/j.arcmed.2020.06.018","relation":{},"ISSN":["0188-4409"],"issn-type":[{"value":"0188-4409","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An Update on Gastroenteropancreatic Neuroendocrine Neoplasms: From Mysteries to Paradigm Shifts","name":"articletitle","label":"Article Title"},{"value":"Archives of Medical Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arcmed.2020.06.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 IMSS. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}